Last updated date
ABOUT THIS STUDY
To evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized
dose schedule with dose adjustment based on clinical response and tolerability, compared to
placebo in subjects with partial seizures
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Seizures
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Have a diagnosis of epilepsy with partial seizures (as defined in the ILAE Classification of Seizures) and be currently taking 1-3 AEDs
- Have a minimum of 4 partial seizures occurring over at least 2 days during the 6-week baseline with no 28-day period free of partial seizures
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Have a treatable cause of seizures
- Are currently receiving treatment with CNS-active compounds (exception: single
antidepressant, hypnotics, and standard AEDs), vigabatrin, Felbatol (felbamate),
Neurontin (gabapentin)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Partial SeizuresPregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
NCT00407797
- Mexico, D. F.
- Acapulco, Guerrero
- Morelia, Michoacan
- Monterrey,, Nuevo Leon
- Monterrey, Nuevo Leon
- Aguascalientes,
- Chihuahua,
- Estado de México,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Partial SeizuresPregabalin Epilepsy Add-On Trial
NCT00141258
- Daegu,
- Daejeon,
- Gwangju,
- Incheon,
- Seoul,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Partial SeizuresPregabalin Versus Levetiracetam In Partial Seizures
NCT00537238
- Duffel,
- Yvoir,
- Kyustendil 2500,
- Pernik,
- Plovdiv,
- Ruse 7002,
- Sofia,
- Sofia,
- Barranquilla, Atlantico
- Bogota, Cundinamarca
- Montes de Oca, San Jose
- San Jose,
- Brno 2,
- Brno,
- Hradec Kralove 3,
- Olomouc,
- Ostrava-Trebovice,
- Praha 4,
- Pribram 8,
- Rychnov nad Kneznou,
- Strasbourg Cedex,
- Toulouse,
- Bonn,
- Hamburg,
- Athens,
- Thessaloniki,
- Pune, Maharashtra
- Chandigarh, Punjab
- Ludhiana, Punjab
- Firenze,
- Foggia,
- Pisa,
- Siena,
- Busan,
- Daejeon,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Kaunas,
- Vilnius,
- Distrito Federal,
- San Luis Potosi,
- Panama,
- Lima,
- Lima,
- Tondo, Manila
- Cebu City,
- Davao City,
- Makati City,
- Manila,
- Quezon City,
- Moscow,
- Moscow,
- Moscow,
- St. Petersburg,
- St. Petersburg,
- St. Petersburg,
- Donostia, Guipuzcoa
- Alicante,
- Barcelona,
- Cordoba,
- Girona,
- Sevilla,
- Kaohsiung,
- Taichung,
- Tainan,
- Capa, Istanbul
- Ankara,
- Cerrahpasa / Istanbul,
- Caracas, Libertador
- Caracas, Miranda
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Pregabalin Epilepsy Add-On Trial | |||
| Official Title ICMJE | Pregabalin Add-On Titration Trial: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Pregabalin (150 mg - 600 mg/Day) Using a Flexible, Optimized Dose Schedule in Subjects With Partial Seizures | |||
| Brief Summary | To evaluate the efficacy of pregabalin as adjunctive therapy, using a flexible, optimized dose schedule with dose adjustment based on clinical response and tolerability, compared to placebo in subjects with partial seizures | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
| Condition ICMJE | Partial Seizures | |||
| Intervention ICMJE | Drug: pregabalin | |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 178 | |||
| Original Enrollment ICMJE | 177 | |||
| Actual Study Completion Date ICMJE | August 2006 | |||
| Primary Completion Date | Not Provided | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Korea, Republic of | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00141258 | |||
| Other Study ID Numbers ICMJE | A0081079 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
| Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | April 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||